固生堂(02273.HK):受託人根據受限制股份獎勵計劃購買合共8萬股
格隆匯12月27日丨固生堂(02273.HK)公吿,於2023年12月27日,現有股份受託人已根據受限制股份獎勵計劃(現有股份)的規則動用約389萬港元以每股股份約48.59港元的平均代價在市場上購買合共8萬股股份,併為合資格參與者的利益以信託方式持有相關股份。
截至2023年12月27日,現有股份受託人已根據受限制股份獎勵計劃(現有股份)的規則購買合共2,363,700股股份,相當於公吿日期公司已發行股份總數約0.96%。按此方式購買的股份將用作受限制股份獎勵計劃(現有股份)項下合資格參與者的獎勵,以激勵彼等對集團作出貢獻。此外,購買股份亦顯示公司對其業務展望及前景充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.